Bruised but stand­ing, Sy­ros braves its way through a $50M IPO

These days, if you want to push a biotech IPO that isn’t di­rect­ly re­lat­ed to gene edit­ing, you bet­ter head to Wall Street sur­round­ed by …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.